Baxter International

Child Organization: Baxter Healthcare

Baxter International Inc. (NYSE: BAX), is an American health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions. The company had 2009 sales of $12.6 billion, across three manufacturing divisions: BioScience (producing recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine; and vaccines); Medication Delivery (producing intravenous solutions and other products used in the delivery of fluids and drugs to patients, as well as inhalation anesthetics and contract manufacturing services); and Renal (providing products to treat end-stage renal disease, or irreversible kidney failure, including solutions and other products for peritoneal dialysis and hemodialysis).

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's June 30, 2012 filing.
Download all contributions to Baxter International

  • Summary

    overview of the committee's finances
    Total Raised:
    $194,146
    Total Spent:
    $236,500
    Cash on Hand:
    $54,070
    Debts:
    $0

Standardized Donation Information

covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.

  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.

  • Republicans vs. Democrats

    in dollars. "Other" includes 3rd parties and organizations without official party affiliation.

  • State vs. Federal

    in dollars

  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Baxter International Sources: OpenSecrets.org

Lobbying

$2,179,500 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of Baxter International

View all lobbying data for Baxter International Sources: OpenSecrets.org

Regulations

5 Mentions; 1 Submissions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Baxter International" in public comments on proposed federal regulations.

  • Documents Submitted by the Organization
    • Submissions
    • Agency
    • Docket
    • Date
    • Toggle 1 FDA Request That FDA Confirm the Agency Will Stay Approval of Abbreviated New Drug Application No. 90-363, for 30 Months Beginning on June 23, 2009 - CLOSED 2011
  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 6 FDA Request That FDA Confirm the Agency Will Stay Approval of Abbreviated New Drug Application No. 90-363, for 30 Months Beginning on June 23, 2009 - CLOSED 2011
    • Toggle 1 FTC Early Termination of Waiting Period under Premerger Rules 2011
    • Toggle 1 FMC Ocean Transportation Intermediary License Applicants 2011
    • Toggle 1 FDA Permit the filing of an Abbreviated New drug application (ANDA) for a Piperacillin and Tazobactam for Injection 2011
    • Toggle 1 FTC Granting of Request for Early Termination of Waiting Period under Premerger Notification Rules 2011